Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) Other Current Receivables: HK$0.75 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09637 Alebund Pharmaceuticals (Jiangsu) Ltd HKSE:09637
5 GF Score
Price HK$25.00
! 1 Warning Sign
View Full Analysis

What is Alebund Pharmaceuticals (Jiangsu) Other Current Receivables?

Alebund Pharmaceuticals (Jiangsu) HKSE:09637 -2.87% 5 Other Current Receivables is HK$0.75 Mil as of Dec. 2025. GuruFocus rates HKSE:09637 with a GF Score™ of 5/100. The stock has 1 warning sign investors should review.

Alebund Pharmaceuticals (Jiangsu)'s Other Current Receivables for the quarter that ended in Dec. 2025 was HK$0.75 Mil.

Alebund Pharmaceuticals (Jiangsu)'s quarterly Other Current Receivables increased from . 20 (HK$0.00 Mil) to Dec. 2024 (HK$14.16 Mil) but then stayed the same from Dec. 2024 (HK$14.16 Mil) to Dec. 2025 (HK$0.75 Mil).

Alebund Pharmaceuticals (Jiangsu)'s annual Other Current Receivables increased from . 20 (HK$0.00 Mil) to Dec. 2024 (HK$14.16 Mil) but then declined from Dec. 2024 (HK$14.16 Mil) to Dec. 2025 (HK$0.75 Mil).

Alebund Pharmaceuticals (Jiangsu) Other Current Receivables Related Terms

Alebund Pharmaceuticals (Jiangsu) Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Alebund Pharmaceuticals (Jiangsu)'s Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alebund Pharmaceuticals (Jiangsu) Other Current Receivables Chart

Alebund Pharmaceuticals (Jiangsu) Annual Data
Trend Dec24 Dec25
Other Current Receivables
14.16 0.75

Alebund Pharmaceuticals (Jiangsu) Semi-Annual Data
Dec24 Dec25
Other Current Receivables 14.16 0.75
HKSE:09637
5GF Score
Alebund Pharmaceuticals (Jiangsu) Ltd HKSE:09637
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alebund Pharmaceuticals (Jiangsu) Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of HK$0.75 Mil mean?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a Other Current Receivables of HK$0.75 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors.
Is Alebund Pharmaceuticals (Jiangsu)'s Other Current Receivables too high?
Alebund Pharmaceuticals (Jiangsu)'s current Other Current Receivables is HK$0.75 Mil. Overall, Alebund Pharmaceuticals (Jiangsu) has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Alebund Pharmaceuticals (Jiangsu)'s Other Current Receivables compare to LLY and JNJ?
Alebund Pharmaceuticals (Jiangsu)'s Other Current Receivables of HK$0.75 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors. Alebund Pharmaceuticals (Jiangsu)'s current Other Current Receivables is HK$0.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alebund Pharmaceuticals (Jiangsu) stock overvalued right now?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a current Other Current Receivables of HK$0.75 Mil. The current Other Current Receivables is HK$0.75 Mil. Alebund Pharmaceuticals (Jiangsu)'s overall GF Score™ is 5/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Alebund Pharmaceuticals (Jiangsu) (HKSE:09637), the current Other Current Receivables is HK$0.75 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alebund Pharmaceuticals (Jiangsu) Business Description

Address No. 7 Jinzhuang Road, Building 7, High-tech Zone, Gaoxin District, Hanjiang District, Jiangsu Province, Yangzhou, CHN
Alebund Pharmaceuticals (Jiangsu) Ltd is a biopharmaceutical company. Along with its subsidiaries, the company is principally engaged in the development, manufacturing, and commercialization of renal products. Its product portfolio in clinical and preclinical stages consists of one Core Product AP301 and six other product candidates, including one late-clinical-stage product candidate AP306, one early-clinical-stage product candidate (AP303), and four preclinical product candidates (AP308, AP304, AP305, and AP307). The company generated revenue from the sales of Mircera in China, a product used in the treatment of renal anemia.
5GF Score

Get the complete analysis for HKSE:09637

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$25.00
Price